PHILADELPHIA - There’s more than one way to mop up after a flu infection. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania report this week in Nature Immunology that a previously unrecognized population of lung immune cells orchestrate the body’s repair response following flu infection.
In addition to the looming threat of a deadly global pandemic, an estimated 200,000 people are hospitalized because of the flu and 36,000 die each year in the US, according to the Centers for Disease Control. However, many influenza-related deaths are not a direct result of the invading virus but instead are linked to the body’s failure to effectively repair and restore lung tissues after it has been damaged by the virus. However, the processes that promote lung tissue repair have remained elusive.
In this new report, David Artis, PhD, associate professor of Microbiology; Laurel Monticelli, a PhD student in the Artis lab; and colleagues observed that flu-infected mice without a population of immune cells called innate lymphoid cells suffered poor lung function leading to eventual death. The team also found that those innate lymphoid cells produced a growth factor called amphiregulin. Infusion of innate lymphoid cells or amphiregulin to the lungs of infected mice normalized lung function, suggesting that the activation of these cells is central to tissue repair at lung surfaces.
Notably, the researchers found that innate lymphoid cells don’t attack the virus per se, as other immune cells do; rather, they spur the proliferation of cells that line the lung, which aids in wound healing of the lung tissues that have been severely damaged as a result of the viral infection.
Based on these findings, this lung cell population could also promote wound healing following other respiratory infections and possibly drive tissue remodeling in situations of non-infectious lung injury and inflammation such as asthma, explains first author Monticelli.
In order to extend these studies to human health, Artis and his team collaborated with researchers at Columbia University to identify a population of innate lymphoid cells that is resident in healthy human lung tissue similar to the cells found in mice. These findings raise the possibility that these cells may also orchestrate lung tissue repair in humans and that targeting activation of innate lymphoid cells through amphiregulin or other proteins may speed tissue recovery in patients suffering from respiratory illnesses.
"The identification of innate lymphoid cells in the lung, and new studies from multiple research groups illuminating their previously unrecognized functions in diverse disease processes could help in the design of new drugs to prevent or better fight many common infectious or inflammatory diseases," concludes Artis.
In addition to Artis and Monticelli, co-authors include Gregory F. Sonnenberg, Michael C. Abt, Theresa Alenghat, Carly G.K. Ziegler, Travis A. Doering, Jill M. Angelosanto, Brian J. Laidlaw, Joshua M. Diamond, Ronald G. Collman and E. John Wherry, all from Penn; Cliff Y. Yang and Ananda W. Goldrath from the University of California, San Diego; and Taheri Sathaliyawala, Masaru Kubota, Damian Turner and Donna L. Farber from Columbia University.
The research was funded by the National Institute Allergy and Infectious Diseases.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.